Millions of Americans who were hoping for a different result from the presidential election have coped with the news in ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Authorities says a man who had posted anti-Trump statements online shot his wife, ex-partner, and two sons before taking his own life.

Once a colonial trading post for the British, Singapore is an incredible city-state in southeast Asia where remnants of the ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (SNSE:GILD) from Buy to Hold. There are 2,850 funds or institutions reporting positions in Gilead ...

Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Earnings Yield Investor model based on the published ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Good afternoon, everyone, and welcome to Gilead's third quarter 2024 earnings conference call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared ...

Full-Year Non-GAAP EPS Guidance: $4.25 to $4.45. Gilead Sciences Inc (NASDAQ:GILD) reported a strong quarter with a 9% growth in HIV sales year-over-year, driven by higher demand and pricing.

Gilead’s Q3 sales increased 7% year-over-year, including 13% year-over-year growth for Biktarvy. The Liver Disease portfolio sales increased 4% to $733 million, and Veklury sales increased 9% ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...